JAMES HERMAN, M.D.
Osteopathic Medicine at Wolfe St, Baltimore, MD
License number
Maryland D43314
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
600 N Wolfe St, Baltimore, MD 21287
Phone
(410) 955-8964
Personal information
See more information about JAMES HERMAN at radaris.comName
Address
Phone
4334 Roland Spring Dr, Baltimore, MD 21210
405 Main St, Betterton, MD 21610
Professional information
See more information about JAMES HERMAN at trustoria.com
Dr. James G Herman, Baltimore MD - MD (Doctor of Medicine)
Dr. James G Herman, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
401 N Broadway St SUITE 1159, Baltimore 21287
(410) 502-3823 (Phone), (410) 502-1419 (Fax)
JOHNS HOPKINS HOSPITAL
401 N Broadway St, Baltimore 21287
(410) 955-8964 (Phone), (410) 955-0115 (Fax)
(410) 502-3823 (Phone), (410) 502-1419 (Fax)
JOHNS HOPKINS HOSPITAL
401 N Broadway St, Baltimore 21287
(410) 955-8964 (Phone), (410) 955-0115 (Fax)
Certifications:
Internal Medicine, 1992, Medical Oncology, 1995
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
401 N Broadway St SUITE 1159, Baltimore 21287
JOHNS HOPKINS HOSPITAL
401 N Broadway St, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
JOHNS HOPKINS HOSPITAL
401 N Broadway St, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
Education:
Medical School
Johns Hopkins University / School of Medicine
Graduated: 1989
Duke University Hospital
Johns Hopkins Sch Med
Johns Hopkins University / School of Medicine
Graduated: 1989
Duke University Hospital
Johns Hopkins Sch Med
Detection And Prognosis Of Lung Cancer
Detection And Prognosis Of Lung Cancer
US Patent:
2011011, May 19, 2011
Filed:
Feb 19, 2009
Appl. No.:
12/867539
Inventors:
Wim Van Criekinge - Sart-Tilman, BE
Josef Straub - Sart-Tilman, BE
Geert Trooskens - Sart-Tilman, BE
Stephen Baylin - Baltimore MD, US
James Herman - Baltimore MD, US
Kornel Schuebel - Baltimore MD, US
Leslie Cope - Baltimore MD, US
Leander Van Neste - Gent, BE
Josef Straub - Sart-Tilman, BE
Geert Trooskens - Sart-Tilman, BE
Stephen Baylin - Baltimore MD, US
James Herman - Baltimore MD, US
Kornel Schuebel - Baltimore MD, US
Leslie Cope - Baltimore MD, US
Leander Van Neste - Gent, BE
Assignee:
ONCOMETHYLOME SCIENCES SA - Sart-Tilman (Liege)
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
C12Q 1/68, G01N 33/574
US Classification:
435 6, 435 723
Abstract:
Methods and tools are provided for detecting and predicting lung cancer. The methods and tools are based on epigenetic modification due to methylation of genes in lung cancer or pre-lung cancer. The tools can be assembled into kits or can be used seperately. Genes found to be epigentically silenced in association with lung cancer include ACSL6, ALS2CL, APC2, ART-S1, BEX1, BMP7, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DPYSL4, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, JAM3, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, SULF2, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655.
James Gordon Herman, Baltimore MD
James Gordon Herman, Baltimore MD
Specialties:
Emergency Medicine, Internal Medicine, Hematology & Oncology, Medical Oncology
Work:
The Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD 21287 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N Broadway St, Baltimore, MD 21287
600 N Wolfe St, Baltimore, MD 21287 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N Broadway St, Baltimore, MD 21287
Education:
Johns Hopkins University (1989)
James G Herman, Baltimore MD
James G Herman, Baltimore MD
Specialties:
Oncologist
Address:
1650 Orleans St, Baltimore, MD 21287
600 N Wolfe St, Baltimore, MD 21287
1215 E Michigan Ave, Lansing, MI 48912
600 N Wolfe St, Baltimore, MD 21287
1215 E Michigan Ave, Lansing, MI 48912
Education:
Johns Hopkins University, School of Medicine - Doctor of Medicine
Genomic Screen For Epigenetically Silenced Genes Associated With Cancer
Genomic Screen For Epigenetically Silenced Genes Associated With Cancer
US Patent:
7794929, Sep 14, 2010
Filed:
Mar 7, 2003
Appl. No.:
10/384491
Inventors:
Stephen B. Baylin - Baltimore MD, US
James Herman - Baltimore MD, US
Hiromu Suzuki - Sapporo, JP
David Sidransky - Baltimore MD, US
James Herman - Baltimore MD, US
Hiromu Suzuki - Sapporo, JP
David Sidransky - Baltimore MD, US
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
A method of identifying epigenetically silenced genes, e. g. , methylation silenced genes, in cancer cells is provided. In addition, methods of identifying a cancer by detecting epigenetic silencing of gene expression are provided, as are methods of treating a subject having such a cancer, for example, a colorectal cancer and/or gastric cancer. Reagents for practicing such methods also are provided.
Early Detection And Prognosis Of Colon Cancers
Early Detection And Prognosis Of Colon Cancers
US Patent:
2008008, Apr 10, 2008
Filed:
Jul 16, 2007
Appl. No.:
11/826508
Inventors:
Stephen Baylin - Baltimore MD, US
Wim van Criekinge - Sart-Tilman (Liege), BE
Kornel Schuebel - Baltimore MD, US
Leslie Cope - Baltimore MD, US
Hiromu Suzuki - Sapporo, JP
James Herman - Baltimore MD, US
Wim van Criekinge - Sart-Tilman (Liege), BE
Kornel Schuebel - Baltimore MD, US
Leslie Cope - Baltimore MD, US
Hiromu Suzuki - Sapporo, JP
James Herman - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
Onomethylome Sciences, S.A. - Leuven
Onomethylome Sciences, S.A. - Leuven
International Classification:
A61K 31/7052, A61K 31/195, A61K 31/7068, C12Q 1/68, C12N 5/00, A61K 31/216
US Classification:
514044000, 435325000, 435006000, 514049000, 514535000, 514562000
Abstract:
A genome wide microarray gene expression approach for human colorectal cancer cells was used to identify hundreds of hypermethylated genes for colon cancer. We compared isogenic cells altered pharmacologically versus genetically to induce genomic demethylation, to pinpoint genes activated by DNA demethylation, but not by inhibition of class I and II histone deacetylases (HDACs). We achieve an 82% success rate in predicting genes with densely hypermethylated CpG islands and complete gene silencing. The genes are similarly hypermethylated in primary tumors and have previously undetected tumor suppressor functions. The genes can be used diagnostically to detect cancer, pre-cancer, and likelihood of developing cancer.